Rustns QD Anti-Corrosion Metal Primer

Hazard statements (CLP)

H315, H317, H319

Code

Statements

H315

Causes skin irritation

SECTION 2: Hazards identification

According to Regulation (EC) No. 1272/2008 (CLP)]

Adverse physicochemical, human health and environmental effects

Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation.

2.2 Label elements

Labelling

Hazard pictograms

GHS07

Signal word

Warning

Contains

5-CHLORO-2-METHYL-2H-ISOTHIAZOL-3-ONE

Hazard statements

H315 - Causes skin irritation. H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation.

Precautionary statements

P102 - Keep out of reach of children. P261 - Avoid breathing dust/fume/gas/mist/vapours/spray. P264 - Wash hands, forearms and face thoroughly after handling. P272 - Contaminated work clothing should not be allowed out of the workplace. P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. P302+P352 - IF ON SKIN: Wash with plenty of water. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P321 - Specific treatment (see supplemental first aid instruction on this label). P333+P313 - If skin irritation or rash occurs: Get medical advice/attention. P337+P313 - If eye irritation persists: Get medical advice/attention. P362+P364 - Take off contaminated clothing and wash it before reuse. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.

Supplemental label elements

EUH208 - Contain1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3- one, May produce an allergic reaction.

2.3 Other hazards

Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %